Background: Liver transplantation is the only life-extending intervention for primary
| INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholangiopathy for which therapy other than liver transplantation is ineffective. 1 While PSC is considered to be a rare disease, 2 it is one associated with significant and disproportionate unmet need, wherein~50% of patients reach a clinical endpoint of death or liver transplantation. 3, 4 Indeed, PSC accounts for >10% of all United
Kingdom liver transplant activity, while also being the lead indication for transplantation in Nordic countries. 5, 6 Although transplantation is a proven life-extending intervention, the incidence of graft loss is significantly greater compared with that observed for non-PSC aetiologies. 7 The vast majority of patients with PSC also develop inflammatory bowel disease (IBD) at some point, predominantly colitis phenotypically. 3, 8 While the clinical course of gut and liver disease do not necessarily parallel, a series of epidemiological findings indicate that co-existence of colitis is associated with poorer transplant-free survival when compared with PSC patients without an IBD history. 3, 9 Moreover, rates of progression to liver transplantation or death may be lower for patients treated with colectomy prior to PSC diagnosis. 10 Following liver transplantation, colectomy does not appear protective against graft loss per se, 11 although data from several centres indicate that retention of an intact colon, particularly one associated with ongoing inflammatory activity post-transplant, increases the risk of developing post-transplant complications including disease recurrence and hepatic artery thrombosis. 7, [12] [13] [14] [15] [16] The definitive, first-line surgical treatment for patients with ulcerative colitis (UC) refractory to medical therapy is a subtotal colectomy. 17 This can either be performed leaving an end ileostomy in situ, or followed by ileorectal anastomosis (IRA), or restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA). In patients with UC alone, health-related global quality of life is similar for 'well-informed' individuals choosing to retain an ileostomy vs those with a pelvic pouch, 18, 19 the latter being opted for in approximately 30% of cases. 20 This rate has remained relatively constant over the last decade and outcomes are generally good for patients without PSC.
In a Nationwide study from Sweden, the pouch failure rates following restorative proctocolectomy were not significantly different between patients with UC alone vs PSC/UC, 21 although other investigators have reported consistently poorer nocturnal pouch function and worse quality of life scores in the latter group, in addition to high rates of recurrent pouchitis, pouch mucosal atrophy and dysplastic change. [22] [23] [24] With respect to the post-liver transplant setting, 58%-62% of patients may develop exacerbating features of acute pouchitis. [25] [26] [27] IRA may also not be favoured given the increased risk of rectal cancer associated with PSC specifically. 28, 29 While the frequency of pouch-related complications is well documented in the PSC literature, the impact of IPAA on graft survival following liver transplantation is ill defined. To this effect, we determined the post-transplant clinical course in PSC patients with an IPAA, specifically compared with those who elected to retain an end ileostomy following their colonic resection, or individuals with colitis yet no colectomy. Our aim was to improve the post-transplant survival estimates for patients and further understand the recipient risk factors contributing to graft loss.
| PATIENTS AND METHODS

| Study population
We reviewed a prospectively collected, well-characterised database of all adult patients undergoing liver transplantation at the University Hospitals Birmingham NHS Foundation Trust from 1990 up to January 2016. The hospital transplant database is maintained prospectively, details of which can be found elsewhere. 30 The immunosuppression protocol for liver transplant recipients across our study period is provided in Table S1 . In order to ensure robustness, accuracy and completeness of data, the transplant database was cross-referenced with an independently accrued registry of all patients having previously attended or under current follow-up of our dedicated PSC clinic. Our intent-to-study population comprised all patients undergoing liver transplantation with PSC and colitis. 
| Clinical endpoints
The "time-dependent" primary clinical endpoint for our study was the incidence rate of first graft loss (death censored). Given the starting point and prolonged observation period of our study, aetiologies of graft loss were classified broadly, according to hepatic artery thrombosis, recurrent biliary stricturing disease in the absence of hepatic artery occlusion, graft rejection, and primary graft nonfunction. Secondary endpoints included the incidence rate of recipient mortality, or graft loss/mortality as a combined outcome measure. Patients were censored at the date of last follow-up if they did not meet the clinical endpoint in question.
| Statistical analysis
Data are presented using the median and interquartile range (IQR)
for continuous variables. The nonparametric Mann-Whitney U test was used to determine whether significant differences existed 
| Quality control and ethical approval
Completeness, plausibility and validity of the data were independently verified (by PJT, JR and ES), including personalised objective review of all historical medical charts. Local regulatory board approval was obtained prior to study initiation and database/chart review (CAB-04186-12 and CARMS-02246). 
| RESULTS
| Characteristics of the patient population
| Colectomy does not protect against liver graft loss or recipient mortality
Overall, 31% of patients with PSC and colitis underwent colectomy (n = 75/240), either prior to or following first liver transplantation and before reaching the primary clinical endpoint. Observing the study cohort in its entirety, the incidence of graft loss or patient mortality was no different between the colectomy vs no colectomy groups ( Figure 2 ), even on restricting analysis to those undergoing colonic resection prior to liver transplantation ( Figure S1 ).
We observed no significant prognostic impact with regard to graft loss conferred by male sex, recipient age at time of transplant or at time of colectomy, pre-transplant MELD score, era in which transplantation was performed, biliary anastomosis type, split liver donation, or organ donation after circulatory death (P value >0.05
for all tested covariates).
| The incidence of graft loss is increased for patients with IPAA
Within the colectomy group, 28% (21/75 patients) subsequently underwent creation of an IPAA, akin to the rate reported for UC patients overall. 20 Formation of IPAA was more common when colonic resection took place prior to liver transplantation (n = 14/21 vs 20/54 patients who retained end an ileostomy, P = 0.024) and when surgery was performed at a younger age (39 vs 49 years, P = 0.001; Table 1 ). Overall, 76 patients from our entire cohort (32%) developed at least one episode of acute rejection, with no significant difference between our three study groups (Chi-square P = 0.710).
All 21 In a direct pairwise comparison, it became apparent that statistically significant differences were attributable to improved liver graft survival experienced by the end ileostomy group vs patients with an
IPAA and compared with the no colectomy group (log-rank P value = 0.005 and 0.044, respectively) ( Figure 3 ). By contrast, the incidence of graft loss was similar between the IPAA group and those without colectomy (P = 0.1). 
Between our colectomy groups more specifically, IPAA was more often fashioned when the indication for colonic resection was active colitis (Table 1) . Nevertheless, the negative impact of IPAA on graft survival was retained in a subanalysis within the latter cohort specifically ( Figure 4 ).
| The incidence of post-transplant complications is attenuated in patients retaining an ileostomy, but not an IPAA
Hepatic artery thrombosis (44%) and recurrent biliary stricturing disease (37%) comprised the principal aetiologies of graft loss in our overall cohort, with lesser contributions from primary graft nonfunction and acute graft rejection (15% and 4%, respectively). per-100-pt-yrs, respectively; log-rank P = 0.007); but not signifi- Tables S2 and S3 .
Our institution and others have previously reported a lower incidence of recurrent biliary stricturing disease post-transplant for patients undergoing colectomy. [12] [13] [14] 16 In the present cohort, we found that this potentially protective effect was confined to patients retaining an end ileostomy ( Figure 5A ), whereas the incidence of No significant differences were seen across our 3 groups in terms of patient mortality or graft loss/mortality as a combined endpoint ( Figure 6 ).
| DISCUSSION
In Europe and North America, the burden of PSC on liver transplant services is substantial, given a critical absence of effective medical Graft loss / mortality F I G U R E 1 Clinical outcomes following liver transplantation for primary sclerosing cholangitis. Kaplan-Meier estimates illustrating the incidence of (A) graft loss, (B) patient mortality, and (C) graft loss/patient morality as a combined endpoint in our overall PSC/colitis cohort undergoing liver transplantation. Incidence rates are presented per 100-patient-years and the respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero is set from the point of liver transplantation. PSC, primary sclerosing cholangitis; Pt. yrs., patient years; Pts. at risk, patients at risk therapy. A societal impact is also evident given the high frequency with which graft loss occurs relative to other aetiologies. 15, 35 As clinicians we strive to provide the best donor organ possible to our patients, as well as identify putative risk factors for loss that sit with the recipient. An interesting observation is the fact that persistence of colitis after transplantation may increase the risk of biliary disease recurrence, [12] [13] [14] 16 although this does not always translate to changes in graft survival. Indeed, many individuals still experience graft loss in the absence of recurrent PSC and despite undergoing colectomy.
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To further understand the clinical course that patient's experience, and to offer better counselling specifically to those needing colonic resection, we examined the impact of colectomy type across a large PSC/UC transplant cohort. In so doing, we identify IPAA as a significant risk factor for graft loss, even for patients undergoing colectomy prior to transplantation or when the impact of colectomy type was determined in time-dependent covariate analysis.
Conversely, graft survival was maximised in the colectomy group retaining an end ileostomy.
The main aetiologies necessitating re-transplantation in our studied cohort were hepatic artery thrombosis or recurrent biliary disease. As discussed, the presence of an intact colon has been put forward as a risk factor for the latter, [12] [13] [14] 16 albeit inconsistently validated. 11,36,37 Herein, we identify that any protective effect conferred following colectomy (with regard to recurrent biliary disease) is skewed towards the patient group retaining an end ileostomy, whereas no benefit is evident for patients with an IPAA. As patients with PSC and IPAA often develop pouchitis and poorer pouch function, 23 it is plausible that persistent or recurrent episodes of intestinal inflammation also contribute to an elevated risk of thrombotic injury, akin to that when the colon is retained. 7, [12] [13] [14] 16, 38 Although speculative, evidence to support this hypothesis includes the fact that our ileostomy group experienced the lowest incidence of hepatic artery thrombosis; in addition to findings that show persistent subclinical intestinal inflammation in PSC associated colitis, 39, 40 associations between pouchitis and thrombocytosis, 41 and heightened platelet activation during active IBD. 42 CumulaƟve incidence (%)
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F I G U R E 2 Post-liver transplant clinical course according to colectomy status. Kaplan-Meier estimates stratified according to colectomy status for all transplanted PSC patients with colitis, specifically for graft loss only (A), mortality only (B) and graft loss/mortality as a combined clinical endpoint (C). Incidence rates are presented per 100-patient-years and the respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero is set from the point of liver transplantation. PSC, primary sclerosing cholangitis; Pt. yrs, patient years; Pts. at risk, patients at risk While speculative, our data argue against the fact that an aggressive 'liver phenotype' post-transplant is driven purely by predisposition towards aggressive IBD. This is because colectomy overall, a marker of colitis activity in its own right, was in itself not a risk factor for re-transplantation. Instead, the negative impact on graft outcome was associated with either (1) retaining an intact colon post-transplant, and by proxy, persistence of ulcerative colitis as a comorbidity, or (2) formation of IPAA in the event colectomy was performed. Detailing the pathogenic mechanisms of PSC and pouchitis are beyond the scope of the current study, but of interest, mucosal dysbiosis has been called into question in both conditions. 43 Whether unique commensal disturbances correlate with risk of allograft recurrence, thromboembolic events or actual graft loss is also an area of ongoing investigation. 44 Given the increased incidence of hepatic artery thrombosis in patients with PSC and IBD, 7,38 which we now confirm is relevant to those with IPAA, a dedicated evaluation of thrombotic tendency is needed in this at-risk population. 45 An early study from the Mayo clinic indicated a 10-year graft loss rate of 12.5% for transplanted PSC patients with an IPAA. 46 The Cleveland Clinic have also published their experience; and in a total cohort of 79 transplanted PSC patients, they also found an increased frequency of hepatic artery thrombosis (27% in the IPAA group vs 18% in the no colectomy group) although surprisingly none went onto be re-transplanted, and a comparative outcomes' analysis against a control ileostomy group was not presented. 27 By contrast, ours is also the first study to robustly determine the impact of colectomy status and type in a time-dependent outcomes' analysis for patients with PSC/UC and show improved graft survival when patients elect to retain an ileostomy.
In selected studies, acute rejection has also been linked to development of recurrent biliary disease post-transplantation, 15 and it is conceivable that alloreactive immune responses may recruit long- IPAA, ileal pouch-anal anastomosis; MELD, model for end-stage liver disease score; UC, ulcerative colitis. a MELD scores not captured for procedures performed prior to January 1994 (n = 36/240; n = 2, 6 and 28 patients in the IPAA, end ileostomy and no colectomy groups, respectively).
having an ileostomy or without colectomy. Moreover, no causal relationship was identified between acute rejection and development of either recurrent biliary disease or graft loss overall.
The therapeutic arena of IBD continues to evolve, and with regard to PSC/colitis specifically, a wealth of attention has focussed in targeting the integrin a4b7. 47, 48 Although this strategy may not impact liver biochemistry, 47 the potential role in attenuating disease progression is of particular interest given that recruitment of a4b7 + mucosal lymphocytes are implicated in the pathogenesis of PSC liver disease, 49 including recurrence post-transplantation for patients with colitis and an intact colon. 15 While a single-centre report, the Birmingham liver unit contributes 25% of all liver transplant activity in the United Kingdom. leading to avoidance in fear of malignant degeneration. A further limitation is that our prospectively captured data records did not include incidence or severity of ischaemia-reperfusion injury (IRI)
specifically, a factor which may have reduced graft viability for certain individuals. Nevertheless, when IRI leads to early graft loss, this is as a result of primary graft nonfunction. The latter occurred in a total of 4 patients across our entire study cohort, all within the no colectomy group (vs no patient with an IPAA or ileostomy).
Moreover, the greatest risk of IRI is in the context of organ donation using marginal grafts, mainly livers donated after circulatory death (DCD), whereas all patients within our IPAA group were recipients of organ donation after brain death.
We must also be mindful that our prolonged study period par- F I G U R E 5 Incidence of recurrent biliary strictures post-transplant. The incidence of recurrent biliary strictures that developed in the absence of hepatic artery occlusion is shown for the overall cohort, stratified by colectomy type. Event rates are depicted for the no colectomy vs ileostomy group in (A) and no colectomy vs the IPAA group in (B). Incidence rates presented per 100-patient-years and the respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero is set from the point of liver transplantation. *5/54 patients in the ileostomy group underwent their colectomy following development of a recurrent biliary stricture, and thus re-assigned to the "no colectomy" group for this analysis. IPAA, ileal pouch-anal anastomosis; PSC, primary sclerosing cholangitis; Pt. yrs, patient years; Pts. at risk, patients at risk F I G U R E 6 Combined patient and graft survival rates. Kaplan-Meier survival estimates of patient mortality (A) and patient mortality/graft loss as a combined endpoint (B) stratified by colectomy type for all transplanted PSC patients with colitis. Incidence rates are presented per 100-patient-years and the respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero is set from the point of liver transplantation. IPAA, ileal pouch-anal anastomosis; PSC, primary sclerosing cholangitis; Pt. yrs., patient years; Pts. at risk, patients at risk strictures collectively, for attributing more specific labels to lesions that developed in the early 1990s (for instance, differentiating ischaemic-type biliary lesions from recurrent PSC) may neither be correct nor consistent with contemporary definitions and imaging modalities. 7, 13 In any event, the lack of protocol cholangiographic/ angiographic surveillance is caveat across most outcome studies in transplantation including our own, and it is conceivable that the subclinical incidence of vascular events and biliary complications is higher than actually reported.
The decision to undergo pouch formation is largely a surgical consideration led by patient choice. 52 However, given an era of organ shortage in liver transplantation, we advocate that all with PSC who require colorectal resection be counselled about potential risks of poorer pouch function compared with UC alone, 23 and also the relatively increased incidence of graft loss, although we cannot be certain of a definite causal relationship between existing pouch and liver transplant failure at this stage. In light of our study findings, the impact of IPAA, pouch function and pouchitis on clinical events as relate to the native liver in PSC also requires investigation, and represents an area of ongoing research activity. Further prospective and independent validation is of the utmost importance in these areas and ideally should proceed via multi-centre collaborative networks and across a globally representative patient population.
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